Skip to main content

Advertisement

Table 1 Demographics, co-morbid conditions and antifungal therapy of study groups.

From: Statins in Candidemia: clinical outcomes from a matched cohort study

Variable Patients on Statins N (% or +/- SD) Patients Not on Statins N (% or SD) p-value†
Age (years) 65.9 (+/- 9.4) 67.7 (+/- 8.7) 0.52
Male 11 (73%) 12 (40%) 0.06
Medical ICU 9 (60%) 24 (80%) 1
Median Charlson Score (IQR) 8 (5-8) 6 (5-7) 0.15
Apache II 14.9 (+/- 3.8) 18.2 (+/- 5.0) 0.03*
AST 20 [17,140] 34 [24,86] 0.34
ALT 22 [19,135] 44 [24,113] 0.17
Albumin 2 (+/- 0.3) 2 (+/- 0.5) 0.76
Bicarbonate 23.9 (+/- 5.6) 22.9 (+/- 5.5) 0.57
Creatinine 2.8 (+/- 2.3) 2.7 (+/- 1.7) 0.80
CPK 129 [39,1502] 45 [35,163] 0.45
Hematocrit 29.8 (+/- 4.2) 29.2 (+/- 4.9) 0.66
PT 14.2 (+/- 2.4) 14.0 (+/- 2.9) 0.79
PTT 31.6 (+/- 8.6) 39.3 (+/- 16.9) 0.06
WBC 12.2 (+/- 4.5) 16.8 (+/- 8.8) 0.02*
Platelets 241 (+/- 127) 221 (+/- 130) 0.62
Heart disease 15 (100%) 16 (53%) <0.01*
Heart failure 7 (47%) 6 (20%) 0.08
Obstructive lung disease 4 (27%) 8 (27%) 1.0
Renal insufficiency 7 (47%) 7 (23%) 0.08
Dialysis 4 (27%) 9 (30%) 1.0
Stroke 6 (40%) 7 (23%) 0.3
Cancer 2 (13%) 4 (13%) 1.0
Diabetes 10 (67%) 17 (57%) 0.75
HIV/AIDS 0 0  
Hypertension 12 (80%) 20 (67%) 0.49
Peripheral vascular disease 5 (33%) 2 (7%) 0.03*
Transplantation 1 (7%) 1 (3%) 1.0
Median duration of Candidemia (days) 2 (+/-0.6) 1 (+/-0.9) 0.2
Survival 11 (73%) 11 (37%) 0.02*
  1. * Significant values, p < 0.05
  2. APACHE II: Acute Physiology and Chronic Health Evaluation II, AST: aspartate transaminase, ALT: alanine transaminase, CPK: creatine phosphokinase, ICU: Intensive Care Unit, IQR; Interquartile range, PT: Prothrombin time, PTT: partial thromboplastin time, WBC; white blood cell count.
  3. †All continue variables presented as mean, standard deviation (SD) except ALT, AST, and CPK, which were non-normally distributed and presented as median with interquartile range.